This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
View All Zacks #1 Ranked Stocks
Zacks News
Select Medical Expands Rehab Footprint Through Vibra Healthcare JV
by Zacks Equity Research
SEM teams up with Vibra Healthcare to run a 76-bed rehab hospital in Southern Kentucky, expanding its post-acute care footprint through a capital-efficient JV.
ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies
by Zacks Equity Research
Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong skin clearance.
JNJ's Nipocalimab Meets Goal in Phase II Study for Systemic Lupus
by Zacks Equity Research
J&J's phase IIb JASMINE study on nipocalimab meets key endpoints in systemic lupus erythematosus, supporting plans to advance the drug into phase III.
FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug
by Zacks Equity Research
Alkermes wins FDA Breakthrough Therapy status for alixorexton in NT1 after Vibrance-1 data shows improvement in wakefulness.
OTLK Stock Crashes 67% in a Week: Here's What You Need to Know
by Zacks Equity Research
Outlook Therapeutics stock plunges 67% in a week after the FDA issues a third CRL rejecting its ONS-5010 BLA for wet AMD, again seeking confirmatory data.
ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH
by Zacks Equity Research
Altimmune shares rally 16.52% after the FDA grants Breakthrough Therapy status to pemvidutide for MASH.
Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase?
by Zacks Equity Research
CELC shares surge as NDA filing and strong phase III data boost optimism around gedatolisib's potential.
ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study
by Zacks Equity Research
Zenas BioPharma tanks nearly 52% despite positive INDIGO study data where obexelimab cut IgG4-RD flare risk by 56% and met all key endpoints.
INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma
by Zacks Equity Research
Incyte's phase III study of Monjuvi combo for first-line DLBCL treatment met primary and key secondary goals, paving the way for a 2026 FDA filing.
Intellia Stock Declines Around 55% in 3 Months: Here's Why
by Zacks Equity Research
NTLA shares plunge 55% in three months after the FDA placed a clinical hold on Nex-Z, suspending trials and milestone guidance following the death of a patient.